Cite
HARVARD Citation
Budde, L. et al. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet oncology. 23 (8), pp. 1055-1065. [Online].